Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02150499
Recruitment Status : Terminated
First Posted : May 30, 2014
Results First Posted : February 3, 2016
Last Update Posted : April 8, 2016
Sponsor:
Information provided by (Responsible Party):
Sunovion

Brief Summary:
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.

Condition or disease Intervention/treatment Phase
Asthma Drug: levalbuterol tartrate HFA inhalation aerosol Drug: placebo Phase 3

Detailed Description:

This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospasm. It is a randomized, double-blind, parallel-group, multicenter, trial of 3 doses of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who present to either the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.

Eligible subjects whose parent(s) or legal guardian(s) provide written informed consent to participate will be randomized to 1 of 2 treatments. Treatment 1 consists of 3 doses, with each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA [cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol]); Treatment 2 consists of 3 doses, with each dose comprised of 8 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff [cumulative dose of 1080 mcg of levalbuterol tartrate HFA inhalation aerosol]). For each Treatment, study medication will be administered every 20 minutes over a period of 1 hour for three doses.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting
Study Start Date : July 2014
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: levalbuterol tartrate HFA inhalation aerosol plus placebo HFA
Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
Drug: levalbuterol tartrate HFA inhalation aerosol
Other Name: Xopenex HFA® (Levalbuterol tartrate) Inhalation Aerosol

Drug: placebo
Experimental: levalbuterol tartrate HFA inhalation aerosol plus levalbuterol
Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
Drug: levalbuterol tartrate HFA inhalation aerosol
Other Name: Xopenex HFA® (Levalbuterol tartrate) Inhalation Aerosol




Primary Outcome Measures :
  1. The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events. [ Time Frame: Week 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  2. The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events. [ Time Frame: Week 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  3. The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation. [ Time Frame: Week 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.


Secondary Outcome Measures :
  1. Change From Baseline in Pulmonary Score (Total Score) to End of Treatment [ Time Frame: Day 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  2. Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment [ Time Frame: Day 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  3. Change From Baseline in Pulmonary Score (Total Score) After Each Dose [ Time Frame: 20 minutes, 40 minutes, 60 minutes ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  4. Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose [ Time Frame: 20 minutes, 40 minutes, 60 minutes ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

  5. Number and Percentage of Subjects Determined to be Stabilized After Treatment [ Time Frame: Day 1 ]
    Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 48 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female from birth to 48 months of age, inclusive, whose parent(s) or legal guardian(s) provide written informed consent prior to study participation and are willing to comply with study procedures.
  2. Subject experiencing acute bronchospasm requiring a bronchodilator and who have a history of wheezing.

Exclusion Criteria:

  1. Subject with a severe illness that, in the opinion of the Investigator, could jeopardize subject safety.
  2. Subject received ≥ 8 puffs (MDI) of a beta-2 agonist or 2.5 mg of nebulized levalbuterol, or albuterol 5.0 mg within 4 hours prior to ED or physician's office admittance.
  3. Subject received ipratropium within 4 hours prior to ED or physician's office admittance.
  4. Subject who participated in an investigational drug study within 30 days prior to enrollment, or who previously participated in the current study.
  5. Subject with a known sensitivity to levalbuterol or racemic albuterol or any of the excipients contained in any of these formulations.
  6. Subject using any prescription drug (including beta-blockers) with which levalbuterol or racemic albuterol sulfate administration is contraindicated.
  7. Subject with a history of clinically significant abnormalities that could interfere with the metabolism or excretion of the study medication (eg, renal, hepatic, metabolic, or endocrine abnormalities).
  8. Subject with a history of cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02150499


Locations
Layout table for location information
United States, Florida
Score Physician Alliance, LLC
Saint Petersburg, Florida, United States, 33710
United States, Illinois
Northern Illinios Research Associates
Dekalb, Illinois, United States, 60115
Northern Illinois Associates
Dekalb, Illinois, United States, 60115
United States, Kentucky
Michael W. Simon, MD, PSC
Nicholasville, Kentucky, United States, 40356
United States, Louisiana
Willis-Knighton Physician Network / Portico Pediatrics
Shreveport, Louisiana, United States, 71105
United States, Michigan
Mid Michigan Sleep Center
Grand Blanc, Michigan, United States, 48439
United States, Missouri
Craig Spiegel, MD
Bridgeton, Missouri, United States, 63044
United States, New Jersey
St. Peter's University Hospital
New Brunswick, New Jersey, United States, 08901
United States, North Carolina
Capital Pediatrics & Adolescent Center PLLC
Raleigh, North Carolina, United States, 27609
Capitol Pediatric & Adolescent Center PLLC
Raleigh, North Carolina, United States, 27609
United States, Ohio
Dayton Clinical Research
Dayton, Ohio, United States, 45406
United States, South Carolina
Charleston Allergy & Asthma Research
Summerville, South Carolina, United States, 29485
United States, Tennessee
Holston Medical Group
Kingsport, Tennessee, United States, 37660
United States, Texas
TTS Research
Boerne, Texas, United States, 78006
Allergy Asthma Research Institute
Waco, Texas, United States, 76712
United States, Virginia
PI-Coor Clinical Research
Burke, Virginia, United States, 22015
Advanced Pediatrics
Vienna, Virginia, United States, 22180
Sponsors and Collaborators
Sunovion
Investigators
Layout table for investigator information
Study Director: Respiratory Medical Director, MD Sunovion

Layout table for additonal information
Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT02150499     History of Changes
Other Study ID Numbers: SEP051-361
First Posted: May 30, 2014    Key Record Dates
Results First Posted: February 3, 2016
Last Update Posted: April 8, 2016
Last Verified: March 2016

Keywords provided by Sunovion:
Acute Asthma exacerbation

Additional relevant MeSH terms:
Layout table for MeSH terms
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action